Search Results

AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated AccuTOX®, one of Defence’s lead products engineered to treat established solid tumors.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin.

Defence Therapeutics Inc. is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its dual Accum®-E7 vaccine, one of Defence’s experimental product designed to treat established cervical cancer.

Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.

Panavance Therapeutics Inc. today announced publication of positive data in the peer-reviewed Anti-Cancer Drugs in an article titled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.”

Hyundai Bioscience announced the positive results from its preclinical study on triple-negative breast cancer, investigating combination therapy of ‘Niclosamide-based oral anti-cancer drug’ jointly developed with CNPharm and Docetaxel, one of widely-used chemical anticancer agents.

AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient.